How doctors assess whether neuropathy is progressing

As I read the medical reviews, doctors rarely decide that neuropathy is progressing from one bad night or one high pain score. They build on your history and examination: how you walk and balance, what your hands can do, and how strength, reflexes and feeling in your feet have changed. Nerve tests help in some situations, but the pattern over time usually says more than any single test.^{1, 2}

I have neuropathy myself, and after a rough week it is natural to wonder whether things are getting worse. This page is about how that question is usually answered, and why following your function tells you more than a pain score alone. It is not a test you can score yourself.

What does “progressing” usually mean in neuropathy?

For a common kind of neuropathy in older adults, change is slow. The CMAJ review describes chronic idiopathic axonal neuropathy as a slowly progressive polyneuropathy, typically starting after the age of 60, and a systematic review in the Journal of Neurology calls it common and usually slowly progressive. In a Dutch study of 56 people with this condition, 33 named walking as the activity that limited them most in daily life.^{1, 3, 4}

As I see it, that is why progression is usually measured in months and years, not days. It also means a follow-up visit is less about today’s symptoms and more about the comparison: are you able to do less than you could last time, and do the findings on examination match that?

Why a bad week isn’t the same as neuropathy progression

Neuropathy symptoms move up and down. The US National Institute of Neurological Disorders and Stroke (NINDS) notes that neuropathic pain is sometimes worse at night and can disrupt sleep. Cleveland Clinic explains some of the reasons: at night there is less to distract you, body temperature drops a little, which damaged nerves may register as pain or tingling, and stress and anxiety can amplify pain signals.^{5, 6}

A flare is real and worth mentioning to your doctor, especially if it keeps you awake. But as I read the research, a worse week after poor sleep, a cold spell or a stressful period is different from a steady loss of something you could do before. The second is what progression means.

What doctors check at a follow-up visit

The history comes first, and it is about everyday function as much as symptoms. A review in the Annals of Indian Academy of Neurology gives examples of what weakness can look like in daily life, such as trouble turning keys, undoing buttons or opening jars. For the feet and legs, I would expect questions about walking and balance too.²

The examination then tests the nerves directly. The same review describes testing vibration and joint position for the large nerve fibres, and pinprick, pain and temperature for the small ones, and notes that unsteadiness in the dark or with the eyes closed suggests large-fibre involvement. A loss of ankle reflexes with reflexes kept elsewhere is typical of the length-dependent kind. An American Family Physician review calls for a comprehensive neurological examination, including muscle bulk and tone.^{2, 7}

Some teams also time simple tasks, such as the 10-metre walk test, a core measure in neurologic physiotherapy, which measures walking speed over a short distance; to track change, it is meant to be repeated.⁸

Structured scales, mostly in inflammatory neuropathy

In chronic inflammatory demyelinating polyneuropathy (CIDP), where treatment decisions depend on whether someone is improving or getting worse, the European Academy of Neurology and Peripheral Nerve Society guideline lists specific measures. Disability can be assessed with the I-RODS and INCAT disability scales, and impairment with a muscle strength score (the MRC sum score), a sensory score and grip strength. For judging response to treatment in CIDP, the guideline also gives thresholds for a meaningful change, for example one point on the INCAT scale or a 10 percent change in grip strength.⁹

These thresholds are still being refined. A 2025 study of 122 people with CIDP in Korea and the UK suggested that a grip-strength change of about 20 percent, or roughly 4.5 to 5 kilograms, may be a better threshold, and found grip strength better at spotting improvement and I-RODS better at spotting deterioration.¹⁰

For the ordinary slowly progressive axonal neuropathy, tools are newer. Researchers writing in Neurology in 2026 noted that no disease-specific, patient-reported measure of functional problems had been available for chronic idiopathic axonal polyneuropathy, and built one. So as I read it, in everyday care your doctor’s comparison of your history and examination is still the main tool.¹¹

Follow up function, not just pain scores

Pain scores from 0 to 10 are useful, but they measure one thing. The IMMPACT group, which set out recommended outcome measures for chronic pain trials, lists physical functioning as its own core area alongside pain, and notes that pain intensity and physical functioning are only modestly associated. A later IMMPACT paper describes asking people for an overall rating of how much they have changed, which can take in pain relief, function and side effects together.^{12, 13}

The CMAJ review notes that most treatment trials count a 30 percent reduction in pain as success, and few people get more than a 50 percent reduction from any single medicine. If pain is the only thing you track, it is easy to miss that you are actually doing more, or less, than before.¹

Here is how I would think about notes for a follow-up. None of this adds up to a score or tells you whether your neuropathy is progressing; it simply gives your doctor concrete examples to compare.

Area	What you could note	What a doctor may compare
Walking	How far you walk before you need a rest, tripping, catching your toes on steps	Strength in the ankles and feet, gait, sometimes a timed walk
Balance and falls	Falls or near-falls, unsteadiness in the dark or in the shower	Balance with eyes closed, position and vibration sense
Hands	Buttons, keys, jars, dropping things, numbness moving into the fingers	Hand strength, sometimes grip strength, sensation in the hands
Where symptoms reach	Whether numbness or tingling has spread further up the legs	The borders of reduced feeling and reflexes
Pain and sleep	Typical and worst nights, what makes it better or worse	Whether pain treatment is working, and side effects
Feet and skin	Sores, blisters, colour changes, swelling	Foot inspection and foot risk, especially with diabetes

Are nerve conduction tests repeated to track neuropathy progression?

Sometimes, but not as a routine. StatPearls describes nerve conduction studies and EMG as helping to show whether a neuropathy is present, and also its cause, severity and outlook. In the guidance I read, I did not find a recommendation to repeat these tests on a schedule just to follow a stable neuropathy.¹⁴

There is also a measurement issue. A study of an automated nerve conduction device in 29 volunteers found that the size of the nerve response (the amplitude) varied more between sessions, by about 16 to 20 percent, than timing measures, which varied by about 4 to 10 percent. As I read it, a small drop on a repeat test can therefore be within normal test-to-test variation, so it is best read together with your history and examination.¹⁵

If you have diabetes: checks on a schedule

Here the follow-up is built in. The American Diabetes Association’s Standards of Care for 2026 recommend assessing everyone with diabetes for neuropathy at least once a year, starting at diagnosis of type 2 diabetes and five years after diagnosis of type 1, with a history, a pinprick or temperature test and a vibration test, plus a yearly 10-gram monofilament test. They also recommend a yearly full foot examination that includes a monofilament test plus at least one other nerve test.¹⁶

The UK guideline NICE NG19 sorts foot risk into categories and suggests reviews once a year at low risk, for example every three to six months at moderate risk, and every one to two months at high risk if there is no immediate concern. To me, moving into a higher risk category is a clear example of a new care need, even if your symptoms feel the same.¹⁷

When a change means you need to be seen sooner

Between the slow drift and an emergency there is a middle ground. The American Family Physician review says more urgent referral is indicated for acute, subacute, severe or progressive symptoms, and the CMAJ review lists uneven symptoms, weakness more than numbness and symptoms not starting in the feet as reasons for urgent specialist referral. NICE counts an ulcer, infection, or an unexplained hot, swollen foot with a change in colour as an active diabetic foot problem.^{7, 1, 17}

My own rule of thumb from reading this: if something you could do a few months ago has become clearly harder, you have fallen, numbness has reached your hands, or you find a sore on your foot, I would not wait for the next routine appointment. I would book an earlier one and bring examples.

Questions you could ask

• What would you count as progression in my kind of neuropathy?
• Which findings from today should we compare next time?
• Would a timed walk or grip-strength measure be useful for me?
• Is there a reason to repeat my nerve tests, and what would a new result change?
• How often should my feet be checked, and by whom?
• Which changes should make me book an earlier appointment?

I’m not a doctor. I’ve written this from published research and guidance, and to help you prepare questions for your own care.

Sources

1. Mirian A, Aljohani Z, Grushka D, Florendo-Cumbermack A. Diagnosis and management of patients with polyneuropathy. CMAJ 2023;195(6):E227–E233. doi:10.1503/cmaj.220936. https://www.cmaj.ca/content/195/6/E227
2. Misra UK, Kalita J, Nair PP. Diagnostic approach to peripheral neuropathy. Annals of Indian Academy of Neurology 2008;11(2):89–97. doi:10.4103/0972-2327.41875. https://pmc.ncbi.nlm.nih.gov/articles/PMC2771953/
3. Zis P, Sarrigiannis PG, Rao DG, Hewamadduma C, Hadjivassiliou M. Chronic idiopathic axonal polyneuropathy: a systematic review. Journal of Neurology 2016;263(10):1903–1910. doi:10.1007/s00415-016-8082-7. https://link.springer.com/article/10.1007/s00415-016-8082-7
4. Erdmann PG, Teunissen LL, van Genderen FR, Notermans NC, Lindeman E, Helders PJM, van Meeteren NLU. Functioning of patients with chronic idiopathic axonal polyneuropathy (CIAP). Journal of Neurology 2007;254(9):1204–1211. doi:10.1007/s00415-006-0501-8. https://link.springer.com/article/10.1007/s00415-006-0501-8
5. National Institute of Neurological Disorders and Stroke (NINDS). Peripheral Neuropathy. Last reviewed 13 March 2026. https://www.ninds.nih.gov/health-information/disorders/peripheral-neuropathy
6. Cleveland Clinic Health Essentials. Why Is Neuropathy Worse at Night? 3 January 2020. https://health.clevelandclinic.org/why-is-neuropathy-worse-at-night
7. Castelli G, Desai KM, Cantone RE. Peripheral Neuropathy: Evaluation and Differential Diagnosis. American Family Physician 2020;102(12):732–739. https://www.aafp.org/pubs/afp/issues/2020/1215/p732.html
8. Academy of Neurologic Physical Therapy. Core Measure: 10 Meter Walk Test (10mWT). Companion document to the core outcome measures clinical practice guideline, J Neurol Phys Ther 2018;42(2):174–220. https://www.neuropt.org/docs/default-source/cpgs/core-outcome-measures/core-measure-10-meter-walk-test-(10mwt)_final.pdf
9. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force – Second revision. J Peripher Nerv Syst 2021;26:242–268. doi:10.1111/jns.12455. Full text hosted by the American Academy of Neurology. https://aanfiles.blob.core.windows.net/guidelines/760ff5a1-a586-44ef-9d5e-e85b6cd850b0/J%20Peripheral%20Nervous%20Sys%20-%202021%20-%20Van%20den%20Bergh%20-%20European%20Academy%20of%20Neurology%20Peripheral%20Nerve%20Society%20guideline%20on.pdf
10. Min YG, Rajabally Z, Ju W, et al. Minimal Clinically Important Difference for the Jamar Hand Grip Dynamometer in CIDP: A Korea-UK Study. European Journal of Neurology 2025;32(8):e70335. doi:10.1111/ene.70335. https://pmc.ncbi.nlm.nih.gov/articles/PMC12376338/
11. van der Star GM, Faber CG, van Doorn PA, et al. Rasch-Built Overall Disability Scale for Chronic Idiopathic Axonal Polyneuropathy. Neurology 2026;107(3):e218266. doi:10.1212/WNL.0000000000218266. https://pmc.ncbi.nlm.nih.gov/articles/PMC13382851/
12. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9–19. doi:10.1016/j.pain.2004.09.012. https://doi.org/10.1016/j.pain.2004.09.012
13. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105–121. doi:10.1016/j.jpain.2007.09.005. https://www.sciencedirect.com/science/article/pii/S1526590007008991
14. Novello BJ, Pobre T. Electrodiagnostic Evaluation of Peripheral Neuropathy. StatPearls [Internet]. StatPearls Publishing; updated 30 January 2023. NBK563169. https://www.ncbi.nlm.nih.gov/books/NBK563169/
15. Kong X, Lesser EA, Gozani SN. Repeatability of nerve conduction measurements derived entirely by computer methods. BioMedical Engineering OnLine 2009;8:33. doi:10.1186/1475-925X-8-33. https://link.springer.com/article/10.1186/1475-925X-8-33
16. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes – 2026. Diabetes Care 2026;49(Suppl. 1):S261–S276. doi:10.2337/dc26-S012. https://doi.org/10.2337/dc26-S012
17. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. NICE guideline NG19. Published 26 August 2015; last updated 11 October 2019. https://www.nice.org.uk/guidance/ng19/chapter/recommendations

Sources checked on 26 September 2026.